CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market sale General Counsel sold 10,000 shares at an average $32.05 ($320,517)
- 4/A Gift President and CEO gave 411,556 shares (gift)
- 4 Grant or award Director acquired 53,635 shares (grant or award)
- 4 Grant or award President and CEO acquired 80,452 shares (grant or award)
- 4 Grant or award General Counsel acquired 22,202 shares (grant or award)
- 4 Grant or award Chief Technical Officer acquired 24,866 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 24,866 shares (grant or award)
- 4 Grant or award EVP of R&D and CMO acquired 24,866 shares (grant or award)
- 4 Open-market sale EVP of R&D and CMO sold 2,798 shares at $38.05 ($106,471)
- 4 Open-market sale President and CEO sold 20,513 shares at $38.57 ($791,271)
- 4 Open-market sale Chief Technical Officer sold 6,164 shares at $38.14 ($235,089)
- 4 Open-market sale General Counsel sold 16,623 shares at an average $37.95 ($630,798)
- 4 Open-market sale Chief Financial Officer sold 8,053 shares at $38.23 ($307,889)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- SC 13G Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
Page 21 of 30 · 587 filings